Efficacy

HR+ POPULATION: PATIENTS COMPLETING PRIOR TRASTUZUMAB ≤ 1 YEAR FROM RANDOMIZATION

NERLYNX prevents recurrence2

Invasive disease-free survival (iDFS) in HER2+, HR+ population: Patients completing prior trastuzumab ≤ 1 year from randomization2

PUMACO 4204 HCP Site Updates 1.5 Charts-04 Created with Sketch.

42% reduction in risk of recurrence*,†

95% of the patients with HER2+, HR+ disease had concomitant endocrine therapy.5

CI: confidence interval; HER2: human epidermal growth factor receptor 2; HR: hazard ratio; HR+: hormone receptor-positive

*Recurrence is defined as an invasive disease event or death.

Results of ExteNET are supported by an exploratory analysis of 5-year follow-up with 74.5% (2117/2840) of patients reconsented.5

Select IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

Please see additional IMPORTANT SAFETY INFORMATION below.


HR+ POPULATION: PATIENTS COMPLETING PRIOR TRASTUZUMAB ≤ 1 YEAR FROM RANDOMIZATION

NERLYNX prevents distant recurrence2

Distant disease-free survival (DDFS) in HER2+, HR+ population: Patients completing prior trastuzumab ≤ 1 year from randomization2

PUMACO 4204 HCP Site Updates 1.5 Charts-01 Created with Sketch.